Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:33412384  

Discovery of a chemical compound that suppresses expression of BEX2, a dormant cancer stem cell-related protein.

Satoshi Saijoh | Mao Nakamura-Shima | Rie Shibuya-Takahashi | Ryo Ito | Akira Sugawara | Tomoko Yamazaki | Takayuki Imai | Yukinori Asada | Kazuto Matsuura | Wataru Iwai | Yuta Wakui | Makoto Abue | Sadafumi Kawamura | Yu Katayose | Haruna Fujimori | Mai Mochizuki | Jun Yasuda | Kazunori Yamaguchi | Kazuo Sugamura | Kennichi Satoh | Yukio Katori | Keiichi Tamai
Biochemical and biophysical research communications | 2021

Cancer stem cells (CSCs) are believed to cause cancer metastasis and recurrence. BEX2 (brain expressed X-linked gene 2) is a CSC-related gene that is expressed in dormant CSCs in cholangiocarcinoma and induces resistance against chemotherapy. The aim of the present study was to identify small compounds that have activity to inhibit BEX2 expression and result in the attenuation of CSC-related phenotypes. We screened 9600 small chemical compounds in high-throughput screening using cholangiocarcinoma cell line HuCCT1 expressing BEX2 protein fused with NanoLuc, and identified a compound, BMPP (1, 3-Benzenediol, [4-(4-methoxyphenyl)-1H-pyrazol-3-yl]). BMPP was found to exert decreasing effects on BEX2 protein expression and G0 phase population of the tumor cells, and increasing effects on ATP levels and chemotherapeutic sensitivity of the cells. These findings indicate that BMPP is a valuable chemical compound for reducing dormant CSC-related phenotypes. Thus, the identification of BMPP as a potential CSC suppressor provides scope for the development of novel therapeutic modalities for the treatment of cancers with BEX2 overexpressing CSCs.

Pubmed ID: 33412384

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


RIKEN BioResource Center (tool)

RRID:SCR_003250

RIKEN BRC contributes to advancement of life science research by collecting, preserving and distributing biological resources such as experimental animals, experimental plants, cultured cell lines, genetic materials (DNA), and associated bioinformatics. The RIKEN BRC develops novel bioresources to promote scientific research and new technologies to increase the value of bioresources, and also to implement effective procedures for the preservation, quality control and usage of bioresources. The RIKEN BRC is working closely with institutions in Japan and abroad.

View all literature mentions

HuCC-T1 (tool)

RRID:CVCL_0324

Cell line HuCC-T1 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Huh-7 (tool)

RRID:CVCL_0336

Cell line Huh-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions